Casgevy (exagamglogene autotemcel) for a UAE family: what the pathway looks like in 2026
*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.
In April 2026, the UAE administered its first Casgevy treatment. The Department of Health Abu Dhabi, the Abu Dhabi Stem Cells Center, and Yas Clinic Hospital brought the world's first CRISPR-edited cell therapy onto UAE soil for a patient with sickle cell disease. The Emirates Drug Establishment has approved the therapy for patients aged 12 and older. For UAE families who have lived with sickle cell disease or transfusion-dependent beta-thalassemia for years, often across generations of a single family, this is a different kind of conversation from the chronic-transfusion world they know.
This page is meant to be the first honest read you get on Casgevy in the UAE, written by the team that would coordinate around your son or daughter's case if you decided to go forward. We assume your treating haematologist has raised this with you, or you have raised it with them.
We will be specific about who Casgevy is currently approved for, what the workup decides, what the journey actually looks like (and it is a longer journey than Elevidys or any one-time infusion), what it costs in AED and US dollars, where it can be given in the UAE, and what life looks like in the year after.
What Casgevy actually is, in plain terms
Casgevy is the first approved CRISPR/Cas9 gene-edited cell therapy anywhere in medicine. It is given as a one-time treatment, but the operational reality is closer to a bone marrow transplant than a one-hour infusion.
Your son or daughter's own hematopoietic stem cells are mobilised out of the bone marrow into the blood, harvested through apheresis sessions, shipped to Vertex's manufacturing facility, edited using CRISPR/Cas9 at the erythroid-specific enhancer region of the BCL11A gene, and returned. The edited cells, once reinfused after myeloablative conditioning, reactivate fetal haemoglobin production. For SCD, fetal haemoglobin reduces sickling. For TDT, it removes the requirement for chronic transfusions.
The edit is permanent. It does not cross to germline cells, your child's future children will not inherit the edit. The change is hereditary only at the haematopoietic stem cell line, in your child's own bone marrow.
What Casgevy is not is a treatment that can be given outpatient. Conditioning is myeloablative. The patient is admitted for the conditioning week, the infusion, and 4 to 6 weeks of recovery during pancytopenia and engraftment. Outpatient follow-up is monthly for the first year.
Who is currently a candidate, and who is not
The current FDA and UAE EDE approved indication is age 12 and older. Your child must have either:
- Sickle cell disease with a history of recurrent vaso-occlusive crises, severe enough that the disease meaningfully interferes with their life, or - Transfusion-dependent beta-thalassemia, defined by a sustained regular transfusion requirement.
The work-up will confirm the diagnosis, the severity criteria, and whether your child is a candidate for myeloablative conditioning. Cardiac, pulmonary, hepatic, and renal function must be adequate. For TDT patients in particular, iron overload from years of transfusion needs to be assessed and managed.
If your child is under 12, Vertex is preparing 2026 submissions to expand the approved age range, but the current indication does not include younger patients. We will not pretend otherwise. Reach out anyway, we can discuss the timeline and what monitoring and supportive care fit between now and a potential future eligibility window.
If your child has SCD that has not produced recurrent VOCs, the case for Casgevy is harder. Most insurers and treatment centres will look for documented VOC history before approving. We are honest about this.
The workup that decides eligibility
Several results need to land before the transplant pathway opens.
Confirmed diagnosis with detailed phenotype and (for SCD) documented VOC history, transfusion history, and prior hydroxyurea response. Your haematologist's records typically cover this.
Bone marrow assessment including cytogenetics.
Cardiac function (echocardiogram, sometimes cardiac MRI for TDT patients with iron overload concerns).
Pulmonary function.
Hepatic function including assessment of any prior hepatitis, iron overload, or transfusion-related hepatic effects.
Renal function.
Iron overload assessment for TDT patients (T2* cardiac MRI, liver iron quantification).
Infectious disease screening, CMV serology, immunisation review.
Fertility preservation counselling, myeloablative conditioning typically causes permanent infertility. For adolescents, gamete preservation (sperm banking for boys, oocyte cryopreservation for girls) needs to be discussed before conditioning starts. This is a culturally sensitive conversation. We do not pretend it is anything other than serious. Your haematologist and the treatment centre's fertility-preservation team will lead it. We support the family with information and logistics.
Psychosocial assessment for the inpatient stay and the long recovery.
A clinical rationale letter from your treating haematologist documents the indication, severity, prior treatment history, and the treatment plan.
The UAE pathway in 2026
The UAE's first Casgevy patient was treated at Yas Clinic Hospital in Abu Dhabi in April 2026, in partnership with the Abu Dhabi Stem Cells Center and under Department of Health Abu Dhabi coordination. The Emirates Drug Establishment is the federal authority approving the therapy. The Abu Dhabi Stem Cells Center brings the bone marrow transplant and cell therapy infrastructure that Casgevy operationally requires.
For a UAE family pursuing Casgevy, the practical pathway is:
- Referral. Your treating haematologist refers to Yas Clinic Hospital or to one of the international authorized treatment centres if you are pursuing the case abroad. For UAE residents, the in-country pathway is now established. - Workup. The treatment centre's transplant team and haematology service complete the candidate assessment. Two to four weeks typically. - EDE coordination. Yas Clinic's pharmacy and the Abu Dhabi Stem Cells Center coordinate the regulatory and procurement layer. - Mobilization and apheresis. G-CSF + plerixafor mobilizes hematopoietic stem cells; apheresis harvests them over multiple sessions. - Vertex manufacturing. The harvested cells go to Vertex's manufacturing facility for CRISPR editing. The waiting period between cell collection and reinfusion is typically 4 to 6 months. - Conditioning. Inpatient busulfan-based myeloablative conditioning, approximately a week before the infusion. - Infusion. Single inpatient infusion of the edited cells. - Recovery. 4 to 6 weeks inpatient during pancytopenia and engraftment. - Follow-up. Monthly for the first year, then less frequent. Long-term haematology monitoring.
For families based in Dubai or other emirates, cross-emirate referral to Yas Clinic Hospital with DHA → DoH coordination is the simplest path. International alternatives include the Sidra Medicine programme in Doha (qualified for 12+ SCD/TDT Casgevy administration) and Vertex's Authorized Treatment Center network in the US and Europe.
If a UAE-based family prefers international treatment, for example to be near family already abroad, or for specific clinician relationships, Reserve Meds can coordinate that pattern.
The cost conversation, in the form a UAE family needs
The Casgevy product list price in 2026 sits at approximately USD 2.2 million, or roughly AED 8.1 million, for the cell-therapy product itself. That is the manufacturer's price. The full cost of care, pre-treatment workup, mobilization, apheresis, the 4-6 month manufacturing waiting period, conditioning, the 4-6 week inpatient transplant admission, supportive care, the first year of monitoring, adds substantially. Total cost of care for cases coordinated cross-border or as cash-pay typically runs USD 2.8-3.5 million, or AED 10.3-12.9 million.
For UAE-resident Emiratis with Thiqa or Daman coverage who are being treated at Yas Clinic Hospital under the public health structure, much of the cost may be underwritten. Your treating haematologist and the Yas Clinic patient navigator are the path to confirm what is currently available. Reserve Meds will not speculate about the public-system financial structure on a public page.
For expatriate UAE residents and self-pay families, the standard cash-pay-with-documentation pattern applies. We separate every line in the quote: cell-therapy product, mobilization drugs, apheresis sessions, conditioning drugs, inpatient admission, supportive care, monitoring labs, our coordination fee. We do not put a markup on the manufacturer's drug price. Our coordination fee is disclosed in writing before any funds move.
Insurance coverage in the UAE for Casgevy is evolving. Daman and the major private insurers handle one-time gene therapies on case-by-case prior authorisation; we provide the documentation packet that increases approval likelihood.
The year after
The first 4 to 6 weeks inpatient are the highest-acuity period. The patient is functionally immunocompromised during the engraftment window; infection prophylaxis, transfusion support, and intensive monitoring run the daily care.
After discharge, the patient is on a structured outpatient follow-up: monthly haematology visits for the first year, with declining frequency thereafter. Transfusion requirement typically falls off within months for TDT patients who achieve engraftment, and VOC frequency typically falls off for SCD patients.
Long-term: lifelong haematology surveillance. The vector is non-integrating from a genomic-insertion standpoint, but lifelong monitoring is standard for any one-time gene therapy. Long-term data accumulation is ongoing globally.
Practical implications for the family: a substantial portion of a year of normal life is reorganised around the treatment. School attendance for adolescent patients will be interrupted for the inpatient and recovery period, we coordinate with the school on tutoring or remote-learning support as needed. Siblings, parents, and the extended family network typically reorganise their schedules around the inpatient admission.
What Reserve Meds does for a UAE family
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For a UAE family pursuing Casgevy, our scope depends on where you choose to be treated.
For families being treated at Yas Clinic Hospital under Thiqa or Daman coverage: we are most useful as a documentation and international second-opinion concierge layer. The Yas Clinic + Abu Dhabi Stem Cells Center programme covers the operational coordination in-country. We can help with international second-opinion clinical reviews from US Authorized Treatment Center transplant specialists, prior-authorisation documentation for private insurance overlays, fertility-preservation logistics if you are routing internationally for that piece, and translation of medical records.
For families pursuing international Casgevy (US or Europe Authorized Treatment Center): standard Reserve Meds scope, regulatory documentation, qualified-centre liaison, named case-lead coordination from intake through one-year follow-up, travel and accommodation logistics for the lengthy stay, and the cross-border financial structure.
For families considering Sidra Medicine, Doha as the alternative: documentation and coordination support; Sidra's in-house Gene Therapy Center handles operational coordination at their end.
Reserve Meds is not your child's prescriber. We do not practise medicine. We do not manufacture Casgevy. We do not own or operate Yas Clinic Hospital, the Abu Dhabi Stem Cells Center, or any other treatment centre. Clinical decisions stay with your treating haematologist and the transplant team.
We work cash-pay (where applicable). Our coordination fee is disclosed in writing.
A note for families weighing this
Sickle cell disease and transfusion-dependent beta-thalassemia have long histories in many Emirati and resident MENA families. We assume you and your wider family have lived with this for years already, often across multiple affected family members. A potentially curative one-time therapy is a different kind of decision than the chronic-care adjustments you have made. We are not trying to push that decision. The right consultation pace is the one your treating haematologist and your family set together.
For Muslim families thinking through the religious-ethical dimension, the Islamic bioethics consensus on disease-modifying therapies that preserve life and function is broadly permissive, including for gene-editing therapies that do not alter the germline. The fertility-preservation conversation has its own religious-ethical layer; families typically consult both their treating clinician and their religious advisor before committing. We will not pressure either conversation.
Families typically take between two and six weeks from first call to readiness for the formal workup. The 4-6 month manufacturing waiting period after cell collection means the total treatment arc is closer to a year. We are honest about that.
What to do if you want to start
If your child meets the basic eligibility (age 12+, SCD with recurrent VOCs or TDT), the first concrete step is a call with our case-lead so we can confirm the right pathway for your family, Yas Clinic Hospital in Abu Dhabi, Sidra Medicine in Doha, or international referral.
If your child is under 12, has SCD without recurrent VOCs, or is in a situation where Casgevy is not currently the answer, reach out anyway. We can discuss timing, supportive care, and alternative options including Lyfgenia for eligible SCD patients.
Most families reach us first on WhatsApp, which we hold open during UAE business hours and on weekends for active cases.
Start your child's case on the portal, or open a WhatsApp conversation with the case-lead and we will take it from there.
Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating haematologist and the transplant team.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.
Regulatory status of Casgevy in United Arab Emirates, 2026
Casgevy (exagamglogene autotemcel) is not currently held on the locally registered medicines list of the Ministry of Health and Prevention (MOHAP). The product is approved by the US Food and Drug Administration per the labelled indication of sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta-thalassemia in patients 12 years and older (see the FDA label at accessdata.fda.gov). The European Medicines Agency holds a parallel marketing authorisation where applicable (see the EMA EPAR at ema.europa.eu).
Because Casgevy is not on the MOHAP locally registered list, access for a United Arab Emirates-based patient runs through the named-patient and personal-import framework that the MOHAP maintains for reference-authority-approved medicines that are not held locally. The official MOHAP portal is at mohap.gov.ae. The qualifying conditions are well established: the medicine is approved by a recognised reference authority (FDA or EMA qualifies); no locally available alternative is clinically equivalent for the specific patient indication; the treating physician of record takes documented clinical responsibility; and chain of custody is preserved end to end from the US source through international transit to the named dispensing facility.
The named-patient and personal-import pathway is the routine framework. For a complex cell or gene therapy that requires a US-certified treatment center, the practical route is patient travel to that certified center rather than import into United Arab Emirates; see Block 2 below for the operational shape on that case type.
Tertiary centers and clinical coordination in United Arab Emirates
The United Arab Emirates tertiary referral network for a Casgevy case is concentrated at Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakhbout Medical City (SSMC), and Tawam Hospital. These centers carry the haematology, oncology, paediatric subspecialty, or rare-disease specialist staffing and the institutional pharmacy and import-license operations that the named-patient pathway requires. For cellular and gene therapies that require leukapheresis collection, AAV infusion, or post-treatment monitoring of a complexity beyond what a community centre is configured for, the case is routinely referred to one of these tertiary centers from the outset.
For cell and gene therapies specifically, the practical access pathway runs through patient travel to a US-certified treatment center (Casgevy authorised treatment centers, Yescarta certified centers, Abecma certified centers, Zolgensma certified centers, Elevidys treatment centers, Hemgenix treatment centers, and so on) rather than import of the cellular or AAV product into United Arab Emirates. The tertiary United Arab Emirates centers handle the upstream referral package assembly (clinical summary, pathology, imaging, organ function panel, infectious disease screen, performance status), the US-side coordination, and the long-term follow-up after the patient returns home. Reserve Meds coordinates the cross-border arc between the United Arab Emirates tertiary team and the US treatment center, including travel and accommodation logistics, financial clearance, and post-treatment data flow.
For oral kinase inhibitors and antibody therapies that can be administered in United Arab Emirates once imported, the tertiary centres dispense and monitor under their institutional pharmacy operations. Reserve Meds handles US-side sourcing under Drug Supply Chain Security Act (DSCSA) chain-of-custody documentation, international shipment to the named dispensing facility, and re-supply cadence aligned to the dosing schedule.
United Arab Emirates pricing reference and payer posture, 2026
Reserve Meds publishes a drug-only US cash-pay reference range at intake and issues a delivered, itemised quote within 24 hours once your treating physician's documentation is in. As an illustrative composite case in the 2026 reference band, the US cash-pay drug-only range for Casgevy sits at approximately USD 2,200,000 to USD 2,400,000 per one-time autologous CRISPR-edited HSC infusion (US wholesale acquisition cost). In AED terms at the 2026 reference rate of 1 USD = 3.670 AED, that translates to a drug-only band of approximately AED 8,074,000 to AED 8,808,000.
Logistics, international shipment, chain-of-custody documentation, cold-chain handling where applicable, US treatment center facility and physician fees where applicable (for cellular and gene therapies, the facility cost commonly equals or exceeds the product cost), Reserve Meds concierge coordination, and any patient and caregiver travel and accommodation are itemised separately. For a cell or gene therapy case the total course cost in 2026 commonly lands at 1.5x to 2.5x the drug-only band once US treatment center fees, lymphodepletion or pre-infusion conditioning, inpatient monitoring, complication management, and family travel and accommodation are added in.
Payer posture in United Arab Emirates is overwhelmingly cash-pay for named-patient imports and cross-border CAR-T cases. Public coverage (DHA Dubai Health Authority and DoH Abu Dhabi insurance schemes) generally does not extend to non-locally-registered specialty cases. Private health insurance plans review case-by-case on a pre-authorisation basis when the documentation package is strong, but cash-pay should be assumed as the default at intake.
Access barriers and how Reserve Meds clears them
The five access barriers we see most often for a Casgevy case in United Arab Emirates are: (1) Regulatory documentation complexity. The MOHAP named-patient and personal-import application package requires a specific bundle (physician clinical rationale letter, prescription, patient identifier, product strength and quantity, chain-of-custody plan, evidence of reference-authority approval, and confirmation that no locally available alternative is clinically equivalent for the patient). Reserve Meds provides physician-facing templates that match the format MOHAP reviewers expect. (2) US-side sourcing and DSCSA chain-of-custody. We coordinate with our US-licensed specialty wholesale partners to secure Casgevy from authorised distribution under the US Drug Supply Chain Security Act, logging every transfer point through to international shipment.
(3) For cell and gene therapies, the US-certified treatment center qualification gate. Casgevy, Yescarta, Carvykti, Abecma, Zolgensma, Elevidys, Hemgenix, and Luxturna can only be administered at a manufacturer-certified treatment center. Reserve Meds maintains the referral arcs to the appropriate US-certified centers and handles the referral package routing, financial clearance, and the multi-week stay coordination. (4) Family logistics. Patient and caregiver travel, accommodation near the treatment center, in-US transport, translator support where needed, and post-treatment data flow back to the treating United Arab Emirates physician are coordinated as a single arc. (5) Insurance and payer posture. Cash-pay is the default. Where private insurance review is contemplated, we supply documentation for the family's submission but we do not bill insurers and we do not adjudicate insurance disputes.
Drug-specific clinical context for Casgevy: the labelled indication is sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta-thalassemia in patients 12 years and older. The relevant clinical-practice guideline body is American Society of Hematology (ASH) 2023 guidelines on sickle cell disease and transfusion-dependent thalassemia at ash.confex.com. Your treating physician of record makes the clinical decision; Reserve Meds is the coordination layer that clears the operational and regulatory barriers between the prescription and the delivered course.
Recent regulatory and access news for Casgevy in United Arab Emirates, 2026
The Ministry of Health and Prevention (MOHAP) portal at mohap.gov.ae has not posted a Casgevy-specific listing on the publicly searchable locally registered medicines list at mohap.gov.ae/en/services/medicine-search as of 2026-06-04. The FDA Drug Safety Communications feed at fda.gov drug-safety-communications and the FDA Drug Shortages list at accessdata.fda.gov drugshortages have not registered a Casgevy-specific safety advisory or shortage signal over the most recent 12-month window. The FDA labelled indication remains sickle cell disease with recurrent vaso-occlusive crises and transfusion-dependent beta-thalassemia in patients 12 years and older (see the current label at accessdata.fda.gov). Vertex Pharmaceuticals in collaboration with CRISPR Therapeutics continues commercial supply per the FDA-labelled indication and the EMA marketing authorisation. The American Society of Hematology (ASH) 2023 guidelines on sickle cell disease and transfusion-dependent thalassemia guidance at ash.confex.com remains the relevant clinical-practice reference. Reserve Meds refreshes this snapshot per case at intake; the snapshot date governs.